Intercept Pharmaceuticals vs. Zenara Pharma: ANDA Patent Consolidation in FXR Agonist Litigation
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Intercept Pharmaceuticals, Inc. v. Zenara Pharma Private, Ltd. |
| Case Number | 1:23-cv-00714 (D. Del.) |
| Court | District of Delaware, before Judge Maryellen Noreika |
| Duration | June 30, 2023 – March 6, 2024 250 days |
| Outcome | Procedural Resolution – Consolidation |
| Patents at Issue | |
| Accused Products | Zenara Pharma’s proposed generic version of Ocaliva® (obeticholic acid) |
Case Overview
The Parties
⚖️ Plaintiff
Innovator pharmaceutical company and developer of Ocaliva® (obeticholic acid), a key FXR agonist therapy for primary biliary cholangitis (PBC).
🛡️ Defendant
Generic pharmaceutical manufacturer seeking regulatory approval for a generic version of Ocaliva® via an ANDA pathway.
The Patent at Issue
This Hatch-Waxman infringement action centered on **U.S. Patent No. RE48,286**, a reissue patent covering steroids as agonists for the Farnesoid X Receptor (FXR), the active mechanism behind Intercept’s branded bile acid therapy Ocaliva® (obeticholic acid). Reissue patents are granted by the USPTO to correct defects in originally issued patents.
- • US RE48,286 — Steroids as agonists for FXR (Farnesoid X Receptor)
Developing a similar pharmaceutical compound?
Identify potential blocking patents in the FXR agonist space before development.
The Verdict & Legal Analysis
Outcome
This case was resolved through **consolidation**, not a trial verdict or settlement on the merits. The action (1:23-cv-00714) was merged into the lead case (C.A. No. 22-1215) for all purposes. No damages were awarded, and no injunctive relief was independently granted within this docket — the substantive merits of infringement and validity remain live issues within the consolidated proceeding.
Key Legal Issues
The consolidation reflects several critical legal and strategic dynamics. The most significant outcome is the **extension of Hatch-Waxman exclusivity protection**. By timely suing on RE48,286, Intercept secured a *separate* 30-month stay running to December 21, 2025, effectively delaying potential generic market entry. This also streamlined a complex multi-patent dispute under a unified protective order and scheduling framework before Judge Maryellen Noreika in the District of Delaware.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical development, especially in the FXR agonist space. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all 7 related Ocaliva® patents
- Analyze Intercept’s patent portfolio for FXR agonists
- Understand Hatch-Waxman stay architecture
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical compound or drug product.
- Input your compound structure or mechanism of action
- AI identifies potentially blocking patents
- Get actionable infringement risk assessment
High Risk Area
FXR agonist compounds and methods
Extended Stay Secured
Until December 2025 for RE48,286
Consolidated Discovery
Efficiency for multi-patent suits
✅ Key Takeaways
Timely assertion against successively filed Paragraph IV certifications can yield independent 30-month stays, extending exclusivity.
Search related Hatch-Waxman cases →Reissue patents introduce unique validity risks (recapture, intervening rights) for generic challengers to assess.
Explore reissue patent analytics →Frequently Asked Questions
The case involved U.S. Patent No. RE48,286, a reissue patent covering steroids as agonists for FXR, listed in the Orange Book for Ocaliva® (obeticholic acid). The consolidated lead case (C.A. No. 22-1215) involves six additional Orange Book patents.
The parties stipulated to consolidation for judicial efficiency. All substantive infringement and validity issues relating to RE48,286 are being litigated within the lead case, C.A. No. 22-1215, before Judge Noreika.
It demonstrates that successive Orange Book patent listings paired with timely Hatch-Waxman suits can extend stay protections by years, materially delaying generic competition in specialty pharmaceutical markets.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Case Docket – C.A. No. 22-1215 (D. Del.)
- USPTO Patent RE48,286
- FDA Orange Book – Ocaliva®
- U.S. Patent and Trademark Office — Reissue Patent Resources
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.